Diagnostic signature of circulating miRNAs in glial brain tumors.

Abstract

e14027 Background: Circulating microRNAs (miRNAs) are currently being investigated as non-invasive diagnostic biomarkers in a wide range of tumors. However, there is still no sufficiently reliable siRNA signature for routine screening of patients with glial tumors of varying degrees of malignancy. Our study aimed to determine the level of microRNA pattern in the blood plasma of patients with glial tumors, which previously showed aberrant expression in tumors. Methods: Relative expression of twenty miRNAs (hsa-miR-3180, hsa-miR-3180-3p, hsa-miR-6782-5p, hsa-miR-182-5p, hsa-miR-133b, hsa-miR-670-3p, hsa-miR-342-3p, hsa-miR-454-3p, hsa-miR-1246, hsa-miR-433-3p, hsa-miR-195-5p, hsa-miR-29a-3p, hsa-miR -107, hsa-miR-21, hsa-miR-122, hsa-let-7c-5p, hsa-miR-125b-5p, hsa-miR-190b, hsa-miR-196a-3p, hsa-miR-16 -5p) was studied in the blood plasma of patients with glial tumors of various grades of malignancy (diffuse astrocytoma (DA, n=10), anaplastic astrocytoma (AA, n=10) and glioblastoma (GB, n=10)) and patients with menigioma (MEN, n=10) compared with a conditionally healthy group (CNTRL, n=10) by RT-PCR. Cycle thresholds were normalized to exogenous cel-miR-39-5p. Relative expression (RE) was calculated using the 2ΔΔCt method. Wilcoxon's t-test and Benjamini-Hochberg multiple comparison adjustment were used to assess differences. Results: As a result of evaluating the relative expression of the studied miRNAs between groups, differences were found for 9 miRNAs. P-values are listed in the Table. Conclusions: Thus, circulating miRNAs could potentially act as biomarkers for both gliomas and their subtypes and differentiate gliomas from meningiomas. The findings may provide new diagnostic strategies for gliomas. Significance levels of differences in the relative expression of miRNAs when comparing the studied groups with each other.[Table: see text]